Nov. 8 at 4:26 PM
$FEMY - So, along with Tuesday's (11/12) Q3 earnings report, we could also see two game-changing catalysts emerge:
**Fast-Track FDA Approval - Already has FDA IDE approval for FINALE trial Part B. FemBloc is approved in Europe, UK, New Zealand and Japan with 99.6% success rate. Any news of Breakthrough Therapy Designation or accelerated approval pathway =
$SPRB- style explosion.
**Big Pharma Buyout - Disruptive, proven technology with global demand. Prime target for Bayer, Merck, Hologic, or Cooper Surgical. A
$5-10 buyout = 380-862% upside.
Float Analysis: Only 25M float with 14.91M avg daily volume = 59% float trading daily. Compare to SPRB's 0.5M float that went +1,378% in one day on FDA news.
Unlike a
$QMMM pump-and-dump, FEMY has real approvals and white knight investor Jorey Chernett aligned for long-term.
Tighten your seatbelts. 🚀
